Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CVSI · OTC · United States · Pharmaceutical Preparations
In shortCV Sciences, Inc. is loss-making, burns cash and carries moderate debt, with revenue shrinking (−12.2% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -3.4% | 5/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -6.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -58.7% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -11.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.03× | 19/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.12× | 49/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -0.91× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -41.23 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -3.7% | 5/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 5 of 5 | 0/100 |
| Revenue growth volatility | 8.6% | 79/100 |
| Operating margin volatility | 43.3% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -5.2% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 20 | 16 | 16 | 16 | 14 |
| Cost of revenue | 11 | 11 | 8.9 | 8.5 | 7 |
| Gross profit | 8.6 | 5.6 | 7.1 | 7.2 | 6.8 |
| Research & development | 1.2 | 0.3 | 0.2 | 0.1 | 0.1 |
| Selling, general & admin | 26 | 12 | 9.7 | 9.2 | 7.6 |
| Operating income | (18) | (6.8) | 3.4 | (2.2) | (0.5) |
| Interest expense | 0 | 0.6 | – | 0.2 | 0.5 |
| Pre-tax income | (16) | (8.3) | 3.1 | (2.4) | (0.9) |
| Income tax | (0.1) | (0) | (0) | (0) | 0 |
| Net income | (16) | (8.2) | 3.1 | (2.4) | (1) |
| Diluted EPS | −$0.14 | −$0.07 | $0.02 | −$0.01 | −$0.01 |
| Diluted shares (millions) | 108 | 138 | 154 | 176 | 184 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−41.23 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026